natural history of patients with advanced cca with fgfr2 gene alterations or wild-type fgfr2
Published 3 years ago • 250 plays • Length 4:51Download video MP4
Download video MP3
Similar videos
-
4:28
proof: infigratinib as first-line therapy in patients with advanced cca
-
2:31
efficacy of second-line chemotherapy in advanced cca with fgfr2 fusions
-
1:45
proof 301: infigratinib in advanced cca
-
7:27
infigratinib for cca
-
10:24
proof 301: infigratinib versus gemcitabine plus cisplatin for cca with fgfr2 rearrangements
-
3:30
final results from fight-202: pemigatinib for patients with fgfr-mutated advanced cholangiocarcinoma
-
57:28
icrn/ens-cca translational science webinar series: "next steps with fgfri”
-
5:06
what is the natural history study of rare solid tumors?
-
2:01
fgfr mutations
-
2:40
the rapid growth of fgfr2 inhibitors: pemigatinib in fight-202
-
4:12
fgfr2 inhibitors in advanced cholangiocarcinoma
-
2:17
fgfr2 gene schematic
-
9:55
fgfr inhibitors in development for cca
-
1:34
advanced cholangiocarcinoma: fgfr2 inhibitors vs chemo
-
1:58
new study links pkcε activation in cancer to aberrant fgfr2 expression
-
2:13
how can i participate in the natural history study of rare solid tumors?
-
30:12
2018 cholangiocarcinoma foundation annual conference #10 - day 2 - fgfr signaling
-
1:16
dr. abou-alfa on remaining questions with infigratinib in fgfr2 cholangiocarcinoma
-
2:27
pan-fgrf inhibitors in different fgfr alteration types across solid tumours